Back to top
more

Immatics (IMTX)

(Delayed Data from NSDQ)

$11.49 USD

11.49
233,000

+0.28 (2.50%)

Updated Aug 26, 2024 04:00 PM ET

After-Market: $11.49 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer

by Zacks Equity Research

AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

by Zacks Equity Research

Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.

Here's Why You Should Invest in BioMarin (BMRN) Stock Now

by Zacks Equity Research

Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.

Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Immatics (IMTX) delivered earnings and revenue surprises of 48.57% and 63.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Gossamer Bio (GOSS) delivered earnings and revenue surprises of -4.35% and 40.10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid

by Zacks Equity Research

Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

by Zacks Equity Research

Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

by Zacks Equity Research

Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 0% and 26.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

by Zacks Equity Research

Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.

Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak

by Zacks Equity Research

Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations. Stock falls during after-market trading.

Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line

by Zacks Equity Research

Madrigal (MDGL) posts better than expected second-quarter numbers. It adds nearly $15 million from sales of the first-ever NASH drug Rezdiffra, which is encouraging for a drug launched in April 2024.

BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View

by Zacks Equity Research

BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.

AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal

by Zacks Equity Research

Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.

Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View

by Zacks Equity Research

Perrigo (PRGO) reports mixed second-quarter 2024 results. It cuts total net sales forecasts primarily due to expected lower distribution in U.S. store brand in second-half 2024.

JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View

by Zacks Equity Research

Jazz's (JAZZ) reports better-than-expected second quarter results. While it revises its guidance for 2024, it withdraws the financial guidance issued as part of the Vision 2025 plan.

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 29.73% and 74.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates

by Zacks Equity Research

United Therapeutics (UTHR) reports mixed second-quarter 2024 results. Tyvaso sales continue to drive the company's top line.

Wall Street Analysts Predict a 54.95% Upside in Immatics (IMTX): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 55% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here's Why 'Trend' Investors Would Love Betting on Immatics (IMTX)

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Immatics (IMTX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Stock Market News for May 15, 2024

by Zacks Equity Research

U.S. stocks closed higher on Tuesday as investors digested the key inflation data that heightened worries regarding inflation.

Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Immatics (IMTX) delivered earnings and revenue surprises of 94.59% and 85.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -22.73% and 94.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy

by Zacks Equity Research

Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.

Immatics (IMTX) Moves 23.2% Higher: Will This Strength Last?

by Zacks Equity Research

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.